1 Eorts to de®ne precisely the role of 5-HT 2B receptors in normal and disease processes have been hindered by the absence of selective antagonists. To address this de®ciency, we developed a series of naphthylpyrimidines as potentially useful 5-HT 2B receptor antagonists. 2 RS-127445 (2-amino-4-(4-¯uoronaphth-1-yl)-6-isopropylpyrimidine) was found to have nanomolar anity for the 5-HT 2B receptor (pK i =9.5+0.1) and 1,000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites. 3 In cells expressing human recombinant 5-HT 2B receptors, RS-127445 potently antagonized 5-HTevoked formation of inositol phosphates (pK B =9.5+0.1) and 5-HT-evoked increases in intracellular calcium (pIC 50 =10.4+0.1). RS-127445 also blocked 5-HT-evoked contraction of rat isolated stomach fundus (pA 2 =9.5+1.1) and (+)a-methyl-5-HT-mediated relaxation of the rat jugular vein (pA 2 =9.9+0.3). RS-127445 had no detectable intrinsic activity in these assays. 4 In rats, the fraction of RS-127445 that was bioavailable via the oral or intraperitoneal routes was 14 and 60% respectively. Intraperitoneal administration of RS-127445 (5 mg kg 71 ) produced plasma concentrations predicted to fully saturate accessible 5-HT 2B receptors for at least 4 h. 5 In conclusion, RS-127445 is a selective, high anity 5-HT 2B receptor antagonist suitable for use in vivo. The therapeutic potential of this molecule is being further evaluated.
Introduction
The 5-HT 2B receptor is a G-protein coupled receptor that was ®rst identi®ed in rat stomach fundus (Clineschmidt et al., 1985; Baez et al., 1990) . Initially termed a 5-HT 1 -like or 5-HT 2F receptor (Kursar et al., 1992) , its subsequent cloning and functional expression revealed structural and transduction properties similar to 5-HT 1C and 5-HT 2 receptors (Foguet et al., 1992; Kursar et al., 1994) . This led to a reorganization of the 5-HT 2 receptor family with this receptor being designated as the 5-HT 2B receptor (Hoyer et al., 1994; Baxter et al., 1995; Hoyer & Martin, 1997) .
5-HT 2B receptors are widely expressed in peripheral tissues of various species. 5-HT 2B receptor mRNA or protein immunoreactivity has been found throughout the gastrointestinal tract including smooth muscle of the stomach fundus, oesophagus, small intestine and colon. The receptor has also been found in the placenta, uterus, lung and prostate. receptors are present in many vascular beds and have been localized to both vascular smooth muscle and vascular endothelial cells (Schmuck et al., 1994; Kursar et al., 1994; Bonhaus et al., 1995; Ullmer et al., 1995; 1996; Choi & Maroteaux, 1996) .
Since activation of 5-HT 2B receptors has been shown to contract stomach and intestinal smooth muscle (Vane, 1959; Baxter et al., 1994; Borman & Burleigh, 1995) , it is likely that a primary function of these receptors is to mediate contractile responses to 5-HT in those smooth muscle tissues in which it is expressed. However, recent ®ndings suggest that 5-HT 2B receptors in vascular endothelium may mediate a nitric oxide-dependent relaxation (Glusa & Richter, 1993; Bodelsson et al., 1993; Ellis et al., 1995) . Thus while the predominant function of peripheral 5-HT 2B receptors in most smooth muscle tissues may be to mediate contraction, their role in vascular tissues may be more complex, depending on the speci®c vascular bed examined and the pathological state of the tissue (Watts et al., 1996) .
Eorts to obtain a more complete understanding of peripheral 5-HT 2B receptors in normal and pathological states have been hampered by the absence of suitable high anity, selective ligands. Most antagonists commonly used to characterize the function of 5-HT 2 receptors, such as mianserin, ritanserin, mesulergine and methysergide, fail to discriminate between 5-HT 2 receptor subtypes. Recently, several 5-HT 2B /5-HT 2C selective antagonists, with low anity for the 5-HT 2A receptor, have been described (Forbes et al., 1995; Nozulak et al., 1995; Kennett et al., 1996) . However, most of these ligands fail to adequately discriminate between the 5-HT 2B and 5-HT 2C receptor subtypes (Baxter, 1996) .
Recently several 5-HT 2B selective ligands have emerged. These include SB 204741 (N-(1-methyl-1H-indol-5-yl)N'-(3-methyl-5-isothiazoyl) urea) which has 100 fold selectivity for the human recombinant 5-HT 2B receptor, albeit with relatively low anity (Bonhaus et al., 1995; Baxter, 1996) and a series of compounds, based on a b-carboline structure, (Audia et al., 1996) . These ligands (e.g., LY-23728: 1-(3,4-dimethoxybenzyl)-2,3,4,9-tetrahydro-1H-b-carboline) are selective for the 5-HT 2B receptor as compared to the 5-HT 2A and 5-HT 2C receptors and have relatively high anity, but their overall receptor speci®city has not been reported nor their suitability for in vivo studies.
To further de®ne the function of 5-HT 2B receptors, and ultimately to test the clinical utility of 5-HT 2B antagonists in various disease states, we initiated a programme aimed at developing selective, high anity 5-HT 2B receptor antagonists suitable for in vivo applications. These eorts yielded a series of naphthylpyrimidines having high anity and selectivity for the 5-HT 2B receptor. The in vitro pharmacology and in vivo pharmacokinetic properties of one of these compounds, RS-127445(2-amino-4-(4 -¯uoronaphth-1-yl) -6 -isopropylpyrimidine) is described in Figure 1 .
Methods

Cell culture
HEK-293 cells stably expressing human recombinant 5-HT 2B receptors were maintained in Dulbecco's modi®ed Eagle's medium supplemented with 10% foetal bovine serum and 250 mg ml 71 G-418. CHO-K1 cells stably expressing the human 5-HT 2A , 5-HT 2B or 5-HT 2C receptors were maintained in Ham's F-12 supplemented with 10% newborn calf serum and 300 mg ml 71 G-418. All cells were cultured in a humidi®ed atmosphere at 378C.
Radioligand binding
CHO-K1 cells expressing human 5-HT 2A , 5-HT 2B or 5-HT 2C receptors were harvested using 2 mM EDTA in phosphate buered saline. Cell membranes were prepared by four cycles of homogenization (Brinkman P10 disrupter) and centrifugation (48,0006g for 15 min). As previously described, each assay was established so as to achieve steady state conditions and to optimize speci®c binding (Bonhaus et al., 1995 3 H]-mesulergine at 328C for 60 min. Nonspeci®c binding was determined using 10 mM methysergide. Assays were terminated by vacuum ®ltration through glass ®bre ®lters (GF/B) which had been pretreated with 0.1% polyethyleneimine. Total and bound radioactivity was determined by liquid scintillation counting. Greater than 90% speci®c binding was achieved in each of these assays.
The selectivity of RS-127445 for 5-HT 2B receptors was further examined by testing the compound for anity at over 100 additional ion channel or receptor binding sites. These studies were conducted by Cerep (Celle L'Evescault France) using standard protocols. ) DMSO with 90% inositol free Ham's F12 medium. Subsequent dilutions were made with inositol free Ham's F12 medium. 5-HT was dissolved in inositol free Ham's F12 medium containing 100 mM LiCl and 1 mM ascorbate. RS-127445, vehicle or other antagonists were pre-incubated with 240 ml of cell suspension at 378c for 20 min. The reactions were initiated by addition of 5-HT. Sixty minutes later, the reactions were terminated by adding 50 ml of ice-cold 20% perchloric acid, chilled in an ice-water bath for 10 min and then neutralized with 160 ml of 1 N KOH. Each sample was diluted with 2 ml of 50 mM Tris-HCl, pH 7.4 at room temperature. The aqueous portion (2.2 ml) was transferred onto Dowex AG1X8 columns (1 ml, 1 : 1, w v 71 ) which had been washed with 5 ml of distilled water. The columns were then washed with 18 ml of distilled water and the inositol phosphates were eluted with 3 ml of 1 N HCl. The eluted radioactivity was determined by liquid scintillation spectroscopy using a Packard 1900CA analyzer. 250 mg ml 71 G-418. After an overnight incubation, the cells were washed three times with Hank's buered saline solution containing 2 mM CaCl 2 , 10 mM HEPES and 2.5 mM probenecid. The cells were incubated with 2 mM Fluo-3 AM in Hank's buered saline solution for 60 min at 378C. The Fluo-3 loaded cells were then washed four times with Hank's buered saline solution.
Inhibition of 5-HT evoked formation of inositol phosphates
Inhibition of 5-HT evoked increases in intracellular calcium
Antagonists were added at least 40 min prior to the addition of agonist. Agonist induced changes in intracellular calcium concentrations were determined at room temperature using a Fluorometric Imaging Plate Reader (Molecular Devices Corporation, Sunnyvale, CA, U.S.A.).
Inhibition of 5-HT evoked contraction of the isolated rat stomach fundus
Functional responses in rat isolated stomach were measured as described by Baxter et al. (1994) . Male Sprague-Dawley rats were euthanized by CO 2 asphyxiation. Longitudinal stomach fundus muscle, devoid of the mucosal layer, was mounted in the longitudinal plane under 1 g tension in a 10 ml organ bath containing Tyrode's physiological salt solution (pH 7.4 at 378C). Antagonists were equilibrated with the tissue for at least 1 h.
Concentration-response curves to 5-HT were then generated in the presence of 0.1 mM pargyline, 30 mM cocaine and 30 mM corticosterone.
Inhibition of (+) a-methyl-5-HT evoked relaxation of the rat jugular vein
Sprague-Dawley rats were euthanized as described above. Right and left external jugular veins were dissected, cleaned of connective tissues and cut into ring segments approximately 5 mm long. Tungsten hooks (0.125 mm diameter) were inserted through the lumen of the vein and connected to tension transducers. Tissues were kept in 10 ml organ baths containing Kreb's solution supplemented with cocaine (30 mM), corticosterone (30 mM), ketanserin (0.3 mM) and indomethacin (3 mM) at 378C at a resting tension of 0.5 g. Prior to the initiation of any studies, monamine oxidases were inactivated by a 30 min pre exposure of the tissue to pargyline (0.1 mM). The veins were then exposed to 0.1 mM U46619 (9,11-dideoxy-9 a, 11 aa-methano-epoxy-PGF2a; a thromboxane A 2 mimetic) until a stable contraction was attained. Acetylcholine (0.1 mM) was used to verify the integrity of the endothelium and to determine the maximum amount of nitric oxide-dependent relaxation that was achievable. After washout of the acetylcholine and recontraction with U46619, cumulative concentration-response curves to (+)-a-methyl-5-HT were constructed. When maximum relaxation was reached, the baths were rinsed, and the tissues were maintained undisturbed for 2 h. Antagonists were then added to the bath and allowed to equilibrate with the tissue for at least 1 h before a second concentration-response curve to (+)-a-methyl-5-HT was generated.
Pharmacokinetics of RS-127445 in rats
Male Sprague-Dawley rats (200 g) were allowed to acclimatize for at least 2 days. The animals were fasted overnight prior to dosing and for 4 h following dosing. Water was allowed ad libitum.
To compare the plasma kinetics of RS-127445 following dierent routes of administration, 90 rats were distributed into three treatment groups of 30 rats each. A single dose of RS-127445 (5 mg kg 71 ) dissolved (2.5 mg ml 71 ) in ethanol:propylene glycol : water (10 : 50 : 40, v v v 71 ), was administered to each rat. At 0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h after dosing, the rats were anaesthetized and blood samples were collected by cardiac puncture.
The relationship between the dose of RS-127445 and the achieved plasma concentration was also examined. Male Sprague-Dawley rats were distributed into three treatment groups. The rats within each group (40) received 1.0, 3.0 or 10.0 mg of RS-127445 by the intraperitoneal route. A blood sample was then collected at 0.5, 1.0, 2.0, 3.0 or 4.0 h following dosing. No more than one blood sample was taken from any one rat. Plasma was stored frozen at 7208C until analysed.
An internal standard was added to aliquots of plasma (0.5 ml) and adjusted to pH 7.2 with phosphate buer. RS-127445 and the internal standard were extracted into ethyl acetate:hexane (1 : 9, v v 71 ). The organic extract was evaporated to dryness under a stream of nitrogen at 388C and dissolved in methanol : phosphate buer (pH 3.0). An aliquot of the dissolved extract was subjected to reverse-phase HPLC on a 15064.6 mm, 5 mm C18 column using a mobile phase of 40% acetonitrile in 50 mM sodium phosphate buer containing 20 mM 1-heptane sulfonic acid (pH 3.0) at a¯ow rate of 1 ml min
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. RS-127225 was detected at a wavelength of 305 nM. The lower limit of quanti®cation of the assay was 4 ng ml 71 . When Hill slopes were found to be not dierent than 1.0, estimates of anity (K i values) were obtained using the ChengPruso equation (Cheng & Pruso, 1973) . The data are presented as a negative log of the K i value (pK i ). For the inositol phosphate studies, EC 50 values for 5-HT concentration-response curves were generated. Estimates of anity (pK B values) were then obtained using Schild regression analysis of the ratios of EC 50 values determined in the presence of at least three dierent concentrations of antagonist. Regression lines with slopes not signi®cantly dierent from 1.0 were constrained to 1.0.
Methods of data analysis
For the calcium in¯ux studies, IC 50 values for antagonist inhibition of 5-HT evoked responses were generated. Since the endpoint of this assay is achieved within seconds of adding the agonist there is no opportunity for the antagonist to reequilibrate to new steady-state levels of binding. Thus, no attempt was made to generate anity estimates on the basis of shifts in agonist-response curves.
For the functional studies using rat isolated stomach fundus or jugular vein, agonist concentration-response curves were generated and Schild regression analysis was conducted using at least three dierent concentrations of antagonist. However, as RS-127445 produced a decrease in the maximum response to 5-HT or (+)a-methyl-5-HT, results from these studies are presented as pA 2 rather than pK B values.
Pharmacokinetic calculations were conducted using standard analytical methods. When concentrations of RS-127445 were below the quanti®cation limit of the assay, the values were set to zero. The peak time to maximum plasma concentration (T max ) and the maximum plasma concentration (C max ) values were estimated by inspection of the plots of the log plasma concentration versus time. The area under the concentration-time curve from 0 ± 8 h (AUC 0 ± 8 ) was calculated using the linear trapezoidal rule. The plasma half-life (T 1/2 ) was determined using the relationship 0.693/b, where b is the elimination rate constant calculated by linear regression analysis of the terminal phase of the log plasma concentration vs time curve. Bioavailability was calculated by dividing the AUC 0 ± 8 obtained following oral or intraperitoneal dosing by the AUC 0 ± 8 obtained with intravenous administration of RS-127445. 
Materials
Results
Radioligand binding
RS-127445 potently displaced [
3 H]-5-HT from human recombinant 5-HT 2B receptors expressed in CHO-K1 cells. The anity (pK i value) of RS-127445 for the 5-HT 2B receptor was 9.5+0.1 (n=9). RS-127445 was selective for the 5-HT 2B receptor, having approximately 1000 fold lower anity for the human recombinant 5-HT 2A , 5-HT 2C , 5-HT 5 , 5-HT 6 and 5-HT 7 receptors, a 5-HT 1A receptor in rat brain membranes, a 5-HT 1B/D receptor in bovine caudate, and a monoamine uptake site in rabbit platelets (Table 1) Eect of RS-127445 on 5-HT evoked increases in the formation of inositol phosphates 5-HT concentration-dependently increased the rate of formation of inositol phosphates in HEK-293 cells expressing the human recombinant 5-HT 2B receptor (pEC 50 value of 8.2+0.1). By contrast, RS-127445, at concentrations up to 100 mM, had no stimulatory eect on inositol phosphate production (Figure 2) . RS-127445 potently inhibited the 5-HT evoked increase in the formation of inositol phosphates in cells expressing 5-HT 2B receptors, producing parallel rightward shifts in the concentration response curves of 5-HT ( Figure 3A) . Schild regression analysis generated a pK B value of 9.5+0.1 with the slope of the Schild regression being not dierent from 1.0 (0.95+0.23) ( Figure 3B ).
Eect of RS-127445 on 5-HT evoked increases in intracellular calcium concentration
5-HT concentration-dependently increased intracellular calcium concentrations in HEK-293 cells expressing 5-HT 2B receptors (pEC 50 value of 9.2+0.1) while RS-127445, at concentrations up to 100 mM, had no stimulatory eect on calcium in¯ux ( Figure 4A ).
RS-127445 potently blocked the 5-HT (10 nM) evoked increases in intracellular calcium concentrations in the HEK-293 cells expressing the 5-HT 2B receptor (pIC 50 value of 10.4+0.1) ( Figure 4B ). The rank-order of potencies of a series of 5-HT 2 receptor antagonists in inhibiting 5-HT evoked inositol phosphate formation and 5-HT mediated increases in intracellular calcium concentrations were similar ( Table 2) .
Eect of RS-127445 on 5-HT evoked contraction of the rat stomach fundus 5-HT concentration-dependently contracted the isolated rat stomach fundus with an pEC 50 value of 8.3+0.2. By contrast, RS-127445, at concentrations from 0.1 ± 10 mM, had no contractile eect on the isolated fundus.
RS-127445 potently blocked the 5-HT evoked contraction of the isolated fundus. The concentration-response curves to 5-HT were shifted to the right in a concentration-dependent manner. There was also a progressive decrease in the maximum response ( Figure 5A ). The intercept value on the Schild regression line corresponded to a pA 2 value of 9.5+1.1. The slope of the regression was statistically signi®cantly less than unity (0.58+0.09) ( Figure 5B ).
To test whether slow dissociation kinetics may have accounted for the insurmountable nature of the antagonism produced by RS-127445, tissues were exposed to RS-127445 (10 nM) and then washed for varying periods of time. Extensive washing of the isolated stomach fundus resulted in a time-dependent reduction in the block produced by RS-127445. However, even after 60 min of washout, the magnitude of the remaining eect corresponded to 50% of the original concentration of RS-127445 ( Figure 6 ).
Eect of RS-127445 on (+)a-methyl-5-HT evoked relaxation of the rat jugular vein
The 5-HT 2B receptor agonist (+)a-methyl-5-HT, in a concentration-dependent manner, relaxed rat isolated jugular veins which had been pre-contracted with the U44619. RS-127445, at concentrations up to 10 mM had no relaxant eect on this preparation but blocked the (+)a-methyl-5-HT mediated response. As was found in the studies with the isolated stomach fundus, RS-127445 produced rightward shifts in the agonistmediated concentration-response curves with progressive decreases in the maximum response attained by (+)amethyl-5-HT ( Figure 7A ). The intercept of the Schild regression line corresponded to a pA 2 value of 9.95+0.07 with a slope not statistically dierent than 1.0 (1.18+0.08) ( Figure 7B ).
In vivo studies with RS-127445 RS-127445 (5 mg kg 71 ) was administered to rats by oral, intraperitoneal and intravenous routes. Peak plasma concentrations were rapidly achieved with the highest concentrations being found at the ®rst time-point measured following intravenous and intraperitonael administration (0.08 h) and by 0.25 h following dosing by the oral route of administration. RS-127445 was cleared from plasma with an estimated terminal elimination half-life of approximately 1.7 h. The bioavailability of RS-127445, when administered by the oral and intraperitoneal routes was approximately 14 and 62% of that obtained by intravenous administration (Figure 8A ). To test whether plasma levels were proportional to the dose administered, RS-127445 was given by the intraperitoneal route at doses of 1, 3 and 10 mg kg
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. Increasing the dose of RS-127445 resulted in proportional increases in its concentration in the plasma ( Figure 8B ).
Discussion
RS-127445 (2-amino-4-(4-¯uoronaphth-1-yl)-6-isopropylpyrimidine) was discovered during the course of studies aimed at developing bioavailable, high anity and selective 5-HT 2B receptor antagonists. RS-127445 was found to have nM anity and 1000 fold selectivity for the 5-HT 2B receptor. RS-127445 is thus among the highest anity, most selective 5-HT 2B receptor ligands to be described (Audia et al., 1996; Baxter, 1996) .
The possibility that RS-127445 had agonist activity at 5-HT 2B receptors was evaluated using cell-based assays and Figure 6 Eect of 1 h of washout on the inhibition of 5-HT-evoked contraction of the rat isolated stomach fundus produced by 0.1 mM RS-127445. Each data point is the means+s.e.mean of at least three dierent determinations. Similar ®ndings were obtained using 1.0 mM RS-127445. HEK-293 cells expressing human recombinant 5-HT 2B receptors. Transfected HEK-293 cells were used for these functional assays because the 5-HT 2B receptor mediated responses were quantitatively greater in this cell line than in the transfected CHO-K1 cells. Both the phospholipase Cmediated conversion of myoinositol into inositol phosphates and the subsequent elevation in intracellular calcium concentrations were used as indices of 5-HT 2B receptor activation (Foguet et al., 1992; Schmuck et al., 1994) . In HEK-293 cells expressing human recombinant 5-HT 2B receptors, 5-HT potently stimulated the formation of inositol phosphates and increased intracellular calcium concentrations. Whereas, RS-127445, at concentrations up to 10 mM, had no stimulatory eect on the formation of inositol phosphates or on intracellular calcium concentrations. Thus, regardless of the endpoint used to measure receptor activation, RS-127445 had no detectable agonist activity at these human recombinant 5-HT 2B receptors.
Consistent with it being a high anity antagonist, RS-127445 potently blocked the 5-HT evoked increase in inositol phosphate formation. The results of Schild regression analysis were consistent with RS-127445 acting in a competitive manner and having nM anity for the receptor. Also consistent with it being a high anity antagonist, RS-127445 blocked the 5-HT evoked increases in intracellular calcium concentrations with a potency 1000 times greater than that of yohimbine.
Since species-species dierences in the pharmacological properties of 5-HT 2B receptors have been reported (Wainscott et al., 1996) , the potency and activity of RS-127445 at endogenous rat 5-HT 2B receptors was also examined. The most extensively characterized 5-HT 2B receptor mediated functional response, and indeed the response that was ®rst used to de®ne the 5-HT 2B receptor, is contraction of the isolated rat stomach fundus (Clineschmidt et al., 1985 ; Baxter et al., 1994; Cox & Cohen, 1995) . Consistent with it being à silent' antagonist RS-127445 produced no detectable response in the isolated stomach fundus but, potently antagonized the contractile response produced by 5-HT. A second functional response which has been attributed to 5-HT 2B receptors is relaxation of the rat jugular vein (Bodelsson et al., 1993; Ellis et al., 1995) . As was found in the studies using isolated stomach fundus, RS-127445 had no detectable intrinsic activity but acted as an antagonist, potently blocking the relaxation produced by the 5-HT 2B receptor agonist a-methyl-5-HT. These ®ndings demonstrate that RS-127445 is a potent antagonist, devoid of intrinsic activity at both endogenous rat and human recombinant 5-HT 2B receptors.
One anomalous ®nding to arise from the functional studies using rat stomach fundus or jugular vein was that the inhibitory actions of RS-127445 could not be fully surmounted with increasing concentrations of agonist. This raised the possibility that RS-127445 may be acting by a noncompetitive mechanism. However, a more plausible explanation is that the experimental conditions did not allow sucient time for steady-state conditions to be achieved following addition of the agonist (Kenakin, 1993) . This possibility is supported by the ®nding that inhibitory actions of RS-127445 were not fully reversed even after washing the tissues in drug-free buer for an hour.
To evaluate the suitability of RS-127445 for studying the role of 5-HT 2B receptors in vivo, its pharmacokinetic properties in the rat were characterized. RS-127445 was rapidly absorbed following both oral and intraperitoneal administration with peak plasma concentrations being achieved within 15 min of dosing. Moreover, the plasma concentrations of RS-127445 that were achieved were proportional to the administered dose. There were no obvious dose or route-dependent limitations to the absorption of RS-127445. Approximately 60% of an intraperitoneal dose and 14% of the oral dose of RS-127445 (5 mg kg 71 ) was bioavailable. The plasma concentrations of RS-127445 that were generated (following intraperitoneal administration of 5 mg kg 71 ) exceeded 20 nM for at least 4 h following dosing. Thus plasma concentrations of RS-127445 which would be predicted to fully saturate accessible 5-HT 2B receptors can be readily achieved and maintained in the rat.
In summary RS-127445 is a novel high anity, selective 5-HT 2B receptor antagonist devoid of detectable intrinsic activity. Moreover, the compound is readily absorbed by various routes of administration. Thus RS-127445 may prove useful in further in vivo studies of 5-HT 2B receptor mediated processes and will be further evaluated as a potential therapeutic agent for the treatment of disorders in which activation of 5-HT 2B receptors may play a pathological role. ) via various routes. Each data point represents the means+s.e.mean for three animals. The peak plasma concentrations of RS-127445 for these routes were 75.7+48.1, 417+298 and 1550+220 ng ml 71 respectively. This entire experiment has been repeated at least three times with similar results. (B) Plasma concentrations of RS-127445 following intraperitoneal dosing with dierent doses of RS-127445. Each data point is the means+s.e.mean of eight animals.
